scholarly journals Marked bone marrow basophilia in a child with acute myeloid leukemia with a cryptic t(8;21)(q22;q22) chromosomal translocation

Leukemia ◽  
2001 ◽  
Vol 15 (11) ◽  
pp. 1799-1801 ◽  
Author(s):  
RB Lorsbach ◽  
R McNall ◽  
S Mathew
Blood ◽  
2020 ◽  
Vol 136 (Supplement 1) ◽  
pp. 37-38
Author(s):  
Elena Zerkalenkova ◽  
Ludmila Zemtsova ◽  
Aleksandra Borkovskaya ◽  
Marina Gaskova ◽  
Marat Kazanov ◽  
...  

Introduction T(X;6)(p11;q23) is a rear but recurrent chromosomal translocation in infant acute myeloid leukemia (AML). It leads to the formation ofMYB-GATA1fusion gene that interferes with granulocyte lineage commitment thus causing AML preliminary with basophilic phenotype. Only males were seen previously in this entity [Dastugue et al. 1997, Belloni et al. 2011, Quelen et al. 2011]. Here we report extensive molecular characterization of 2 infant AML cases with t(X;6)(p11;q23)/MYB-GATA1enrolled in the Russian AML registration study with one of them being a girl. Case reports A boy aged 5,5 mo. with WBC 27,7*109/L and 45% blasts in bone marrow was diagnosed AML, M5a by morphological, cytochemical and immunological observations. He was treated according to AML-BFM-2004 protocol and received allogenic HSCT from matched unrelated donor in the first remission. Patient stays in complete remission for 4 years now. A girl aged 8 mo. was headed to a hospital with febrile fever and petechiae. She had initial WBC 33,8*109/L and 35% bone marrow blasts of basophilic phenotype. Spinal tap confirmed CNS involvement (cytosis 2,6/mm3, 3% blasts). Patient received induction therapy (cytarabine, etoposide, daunorubicin) and achieved a complete remission. However, she developed severe myelodepression and died of infection 3 mo. after the diagnosis. Results MYB-GATA1.GTG-banded karyotyping showed a rearrangement between chromosomes 6 and X as a sole abnormality in both patients - insertion of chromosome 6 material into Xp11 band in a boy and reciprocal translocation t(X;6)(p11;q23) in a girl. FISH for relevant age-specific translocations, includingKMT2Arearrangements and t(7;12)(q36;p12)/ETV6-HLXB, was negative. RNA-seq (TruSeqRNA, Illumina, San-Diego, CA, USA) revealedMYB-GATA1fusion expression with exon 8 - exon 5 junction identical in both patients which was validated by RT-PCR and Sanger sequencing. Direct genomic PCR confirmed breakpoints withinMYBintron 8 andGATA1intron 4 and uncovered patient-specific junctions (see Figure). Reciprocal fusions.The formation of reciprocal fusions was also shown in two studied patients. A boy demonstratedGATA1-TUBE(6q21) intron 4 - intron 7 junction. It is non-functional due to tail-to-tail transcriptional orientation. Such structures are likely to form sinceMYBandGATA1are located in an opposite genomic orientation, so our finding goes in line with previous unsuccessful attempts to look for reciprocalGATA1fusion transcripts expression [Quelen et al. 2011]. However, a girl patient had reciprocalGATA1-CD164fusion (exon 4 - exon 6) actively transcribed together with third fusionMYB-CD164. On the one hand, this confirms that additional event such as inversion of either chromosomal fragment is required for t(X;6)(p11;q23) to manifest. On the other hand, this is, to our knowledge, the first demonstration of reciprocalGATA1fusion transcript expression inMYB-GATA1-associated AML. Wild-type MYB and GATA1 expression.AlongsideMYB-GATA1expression both patients demonstrated the overexpression of wild-typeMYBby qPCR. This is in agreement with MYB overexpression being a feature of undifferentiated cells and diminishing during differentiation [Bartunek et al. 2003]. Wild-typeGATA1expression (its lossper se) is of key importance inMYB-GATA1-associated AL. It was previously proposed that the loss of wild-typeGATA1is essential for leukemogenesis in male patients as the only copy of this gene is disturbed by chromosomal translocation [Quelen et al. 2011]. We observed no wild-typeGATA1expression in our male patient. However, in the female patient wild-type GATA1 expression was present. Additional events.The samples were also screened for additional genetic events associated with myeloid neoplasia by targeted DNA NGS (QIAact Myeloid DNA UMI Panel, Qiagen, Hilden, Germany), fragment analysis (NPM1,FLT3-ITD) and Sanger sequencing (cKIT,FLT3-TKD). NoFLT3,NPM1and cKIT pathogenic variants were found. NoGATA1truncating mutations were found. Deleterious variants were found inNRASgene (p.G12C in a boy, p.G13D in a girl). Female patient also demonstrated pathogenic variants inKRAS(p.A59E) andJAK2(p.N683G). Conclusions Thus, here we report a first case of female patient with t(X;6)(p11;q23)/MYB-GATA1. This raises a question whetherGATA1insufficiency is the primary mechanisms of leukemogenesis in this genetic subgroup. Figure Disclosures No relevant conflicts of interest to declare.


2019 ◽  
Vol 18 (14) ◽  
pp. 1936-1951 ◽  
Author(s):  
Raghav Dogra ◽  
Rohit Bhatia ◽  
Ravi Shankar ◽  
Parveen Bansal ◽  
Ravindra K. Rawal

Background: Acute myeloid leukemia is the collective name for different types of leukemias of myeloid origin affecting blood and bone marrow. The overproduction of immature myeloblasts (white blood cells) is the characteristic feature of AML, thus flooding the bone marrow and reducing its capacity to produce normal blood cells. USFDA on August 1, 2017, approved a drug named Enasidenib formerly known as AG-221 which is being marketed under the name Idhifa to treat R/R AML with IDH2 mutation. The present review depicts the broad profile of enasidenib including various aspects of chemistry, preclinical, clinical studies, pharmacokinetics, mode of action and toxicity studies. Methods: Various reports and research articles have been referred to summarize different aspects related to chemistry and pharmacokinetics of enasidenib. Clinical data was collected from various recently published clinical reports including clinical trial outcomes. Result: The various findings of enasidenib revealed that it has been designed to allosterically inhibit mutated IDH2 to treat R/R AML patients. It has also presented good safety and efficacy profile along with 9.3 months overall survival rates of patients in which disease has relapsed. The drug is still under study either in combination or solely to treat hematological malignancies. Molecular modeling studies revealed that enasidenib binds to its target through hydrophobic interaction and hydrogen bonding inside the binding pocket. Enasidenib is found to be associated with certain adverse effects like elevated bilirubin level, diarrhea, differentiation syndrome, decreased potassium and calcium levels, etc. Conclusion: Enasidenib or AG-221was introduced by FDA as an anticancer agent which was developed as a first in class, a selective allosteric inhibitor of the tumor target i.e. IDH2 for Relapsed or Refractory AML. Phase 1/2 clinical trial of Enasidenib resulted in the overall survival rate of 40.3% with CR of 19.3%. Phase III trial on the Enasidenib is still under process along with another trial to test its potency against other cell lines. Edasidenib is associated with certain adverse effects, which can be reduced by investigators by designing its newer derivatives on the basis of SAR studies. Hence, it may come in the light as a potent lead entity for anticancer treatment in the coming years.


2021 ◽  
Vol 22 (13) ◽  
pp. 6857
Author(s):  
Samantha Bruno ◽  
Manuela Mancini ◽  
Sara De Santis ◽  
Cecilia Monaldi ◽  
Michele Cavo ◽  
...  

Acute myeloid leukemia (AML) is a hematologic malignancy caused by a wide range of alterations responsible for a high grade of heterogeneity among patients. Several studies have demonstrated that the hypoxic bone marrow microenvironment (BMM) plays a crucial role in AML pathogenesis and therapy response. This review article summarizes the current literature regarding the effects of the dynamic crosstalk between leukemic stem cells (LSCs) and hypoxic BMM. The interaction between LSCs and hypoxic BMM regulates fundamental cell fate decisions, including survival, self-renewal, and proliferation capacity as a consequence of genetic, transcriptional, and metabolic adaptation of LSCs mediated by hypoxia-inducible factors (HIFs). HIF-1α and some of their targets have been associated with poor prognosis in AML. It has been demonstrated that the hypoxic BMM creates a protective niche that mediates resistance to therapy. Therefore, we also highlight how hypoxia hallmarks might be targeted in the future to hit the leukemic population to improve AML patient outcomes.


2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Naglaa M. Hassan ◽  
Fadwa Said ◽  
Roxan E. Shafik ◽  
Mona S. Abdellateif

Abstract Background Acute myeloid leukemia (AML) is a heterogeneous malignant disease characterized by accumulation of different types of mutations commonly the CCAAT/enhancer binding protein-alpha (CEBPA). However, the dysregulations of CEBPA expression in AML is still a debatable issue. The aim of the current study was to assess CEBPA gene expression in bone marrow (BM) aspiration specimens of 91 AML patients, compared to 20 control donors of bone marrow transplantation (BMT), using RT-PCR. Data were correlated with patients’ clinico-pathological features, response to treatment, progression-free survival (PFS), and overall survival (OS) rates. Results There was overexpression of CEBPA gene in AML patients compared to normal control [1.7 (0.04–25.6) versus 0.17 (0–4.78), respectively, P < 0.001]. Upregulation of CEBPA expression associated significantly with increased BM hypercellularity, total leucocyte counts, peripheral blood blast cell count, and poor PFS (P < 0.001, 0.002, 0.001, and 0.013, respectively). There was no significant association between CEBPA expression and any other relevant clinico-pathological features or OS rates (P = 0.610) of the patients. ROC analysis for biological relevance of CEBPA expression with AML showed that sensitivity and specificity of CEBPA expression at a cut-off value of 0.28 are 92.3% and 78.6%, respectively (P < 0.001). All patients who had CEBPA overexpression and mutant FLT3 showed BM hypercellularity, adverse cytogenetic risk, increased TLC, and PB blast cells count (P = 0.007, P < 0.001, 0.016, and 0.002, respectively). Conclusion CEBPA overexpression could be used as a genetic biological marker for AML diagnosis, as well as a poor prognostic factor for disease progression. It has no impact on OS rates of the patients.


2021 ◽  
Vol 10 (1) ◽  
Author(s):  
Yiyi Yao ◽  
Fenglin Li ◽  
Jiansong Huang ◽  
Jie Jin ◽  
Huafeng Wang

AbstractDespite the advances in intensive chemotherapy regimens and targeted therapies, overall survival (OS) of acute myeloid leukemia (AML) remains unfavorable due to inevitable chemotherapy resistance and high relapse rate, which mainly caused by the persistence existence of leukemia stem cells (LSCs). Bone marrow microenvironment (BMM), the home of hematopoiesis, has been considered to play a crucial role in both hematopoiesis and leukemogenesis. When interrupted by the AML cells, a malignant BMM formed and thus provided a refuge for LSCs and protecting them from the cytotoxic effects of chemotherapy. In this review, we summarized the alterations in the bidirectional interplay between hematopoietic cells and BMM in the normal/AML hematopoietic environment, and pointed out the key role of these alterations in pathogenesis and chemotherapy resistance of AML. Finally, we focused on the current potential BMM-targeted strategies together with future prospects and challenges. Accordingly, while further research is necessary to elucidate the underlying mechanisms behind LSC–BMM interaction, targeting the interaction is perceived as a potential therapeutic strategy to eradicate LSCs and ultimately improve the outcome of AML.


2016 ◽  
Vol 55 (13) ◽  
pp. 1821-1822 ◽  
Author(s):  
Tamaki Nashiro ◽  
Hirotsugu Hashimoto ◽  
Hajime Horiuchi ◽  
Kensuke Usuki

Sign in / Sign up

Export Citation Format

Share Document